1887

Journal of Medical Microbiology logo

Volume 73, Issue 9

Current status of clinical trials for phage therapy Open Access

Abstract

Recently, bacteriophages have been considered alternatives to antibacterial treatments. Infectious diseases continue to plague the world because bacteria can adapt and develop defence mechanisms against antibiotics. The growing incidence of antibiotic-resistant bacterial infections necessitated the development of new techniques for treating bacterial infections worldwide. Clinical trials have shown efficiency against antibiotic-resistant bacteria. However, scientists in future clinical trials should scrutinize phage resistance implications, assess combination strategies with antimicrobial agents and address challenges in phage therapy delivery for effective implementation.

  • Received:
  • Accepted:
  • Published Online:
Keyword(s): antimicrobial resistance , bacteriophage therapy , clinical trials , infections and phage engineering
© 2024 The Authors
  • This is an open-access article distributed under the terms of the Creative Commons Attribution License. This article was made open access via a Publish and Read agreement between the Microbiology Society and the corresponding author’s institution.
Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.001895
2024-09-25
2024-10-13
Loading full text...

Full text loading...

/deliver/fulltext/jmm/73/9/jmm001895.html?itemId=/content/journal/jmm/10.1099/jmm.0.001895&mimeType=html&fmt=ahah

References

  1. de Kraker MEA, Stewardson AJ, Harbarth S. Will 10 million people die a year due to antimicrobial resistance by 2050?. PLoS Med 2016; 13:e1002184 [View Article] [PubMed]
     [Google Scholar]
  2. Lin DM, Koskella B, Lin HC. Phage therapy: an alternative to antibiotics in the age of multi-drug resistance. World J Gastrointest Pharmacol Ther 2017; 8:162–173 [View Article] [PubMed]
     [Google Scholar]
  3. Abedon ST, Thomas-Abedon C. Phage therapy pharmacology. Curr Pharm Biotechnol 2010; 11:28–47 [View Article] [PubMed]
     [Google Scholar]
  4. Hobbs Z, Abedon ST. Diversity of phage infection types and associated terminology: the problem with “Lytic or lysogenic.”. FEMS Microbiol Lett 2016; 363:47 [View Article] [PubMed]
     [Google Scholar]
  5. Kondo K, Kawano M, Sugai M. Distribution of antimicrobial resistance and virulence genes within the prophage-associated regions in nosocomial pathogens. mSphere 2021; 6: [View Article]
     [Google Scholar]
  6. Düzgüneş N, Sessevmez M, Yildirim M. Bacteriophage therapy of bacterial infections: the rediscovered frontier. Pharmaceuticals 2021; 14:34 [View Article]
     [Google Scholar]
  7. Gupta P, Singh HS, Shukla VK, Nath G, Bhartiya SK. Bacteriophage therapy of chronic nonhealing wound: clinical study. Int J Low Extrem Wounds 2019; 18:171–175 [View Article] [PubMed]
     [Google Scholar]
  8. Chan BK, Turner PE, Kim S, Mojibian HR, Elefteriades JA et al. Phage treatment of an aortic graft infected with Pseudomonas aeruginosa. Evol Med Public Health 2018; 2018:60–66 [View Article] [PubMed]
     [Google Scholar]
  9. Kifelew LG, Warner MS, Morales S, Vaughan L, Woodman R et al. Efficacy of phage cocktail AB-SA01 therapy in diabetic mouse wound infections caused by multidrug-resistant Staphylococcus aureus. BMC Microbiol 2020; 20:204 [View Article] [PubMed]
     [Google Scholar]
  10. Taati Moghadam M, Amirmozafari N, Shariati A, Hallajzadeh M, Mirkalantari S et al. How phages overcome the challenges of drug resistant bacteria in clinical infections. Infect Drug Resist 2020; 13:45–61 [View Article] [PubMed]
     [Google Scholar]
  11. Principi N, Silvestri E, Esposito S. Advantages and limitations of bacteriophages for the treatment of bacterial infections. Front Pharmacol 2019; 10:513 [View Article] [PubMed]
     [Google Scholar]
  12. Pendleton JN, Gorman SP, Gilmore BF. Clinical relevance of the ESKAPE pathogens. Expert Rev Anti Infect Ther 2013; 11:297–308 [View Article] [PubMed]
     [Google Scholar]
  13. Oechslin F. Resistance development to bacteriophages occurring during bacteriophage therapy. Viruses 2018; 10:351 [View Article] [PubMed]
     [Google Scholar]
  14. McCallin S, Oechslin F. Bacterial Resistance to Phage and Its Impact on Clinical Therapy. Phage Therapy: A Practical Approach Switzerland AG: Springer International Publishing; 2019 pp 59–88
     [Google Scholar]
  15. Parfitt T. Georgia: an unlikely stronghold for bacteriophage therapy. Lancet 2005; 365:2166–2167 [View Article]
     [Google Scholar]
  16. Tao P, Zhu J, Mahalingam M, Batra H, Rao VB. Bacteriophage T4 nanoparticles for vaccine delivery against infectious diseases. Adv Drug Deliv Rev 2019; 145:57–72 [View Article] [PubMed]
     [Google Scholar]
  17. Kowalska JD, Kazimierczak J, Sowińska PM, Wójcik EA, Siwicki AK et al. Growing trend of fighting infections in aquaculture environment—opportunities and challenges of phage therapy. Antibiotics 2020; 9:301 [View Article]
     [Google Scholar]
  18. Uyttebroek S, Chen B, Onsea J, Ruythooren F, Debaveye Y et al. Safety and efficacy of phage therapy in difficult-to-treat infections: a systematic review. Lancet Infect Dis 2022; 22:e208–e220 [View Article] [PubMed]
     [Google Scholar]
  19. Tkhilaishvili T, Winkler T, Müller M, Perka C, Trampuz A. Bacteriophages as adjuvant to antibiotics for the treatment of periprosthetic joint infection caused by multidrug-resistant Pseudomonas aeruginosa. Antimicrob Agents Chemother 2019; 64:e00924-19 [View Article] [PubMed]
     [Google Scholar]
  20. Doub JB, Ng VY, Wilson E, Corsini L, Chan BK. Successful treatment of a recalcitrant Staphylococcus epidermidis prosthetic knee infection with intraoperative bacteriophage therapy. Pharmaceuticals 2021; 14:231 [View Article] [PubMed]
     [Google Scholar]
  21. Gordillo Altamirano FL, Barr JJ. Phage therapy in the postantibiotic era. Clin Microbiol Rev 2019; 32: [View Article]
     [Google Scholar]
  22. Hatfull GF, Dedrick RM, Schooley RT. Phage therapy for antibiotic-resistant bacterial infections. Annu Rev Med 2022; 73:197–211 [View Article] [PubMed]
     [Google Scholar]
  23. Kortright KE, Chan BK, Koff JL, Turner PE. Phage therapy: a renewed approach to combat antibiotic-resistant bacteria. Cell Host Microbe 2019; 25:219–232 [View Article] [PubMed]
     [Google Scholar]
  24. Study Record ClinicalTrials.gov. n.d https://clinicaltrials.gov/study/NCT04191148?tab=results accessed 26 September 2023
  25. BacterioPHAGE for Gastrointestinal Health 2 Study - Full Text View - ClinicalTrials.gov. n.d https://classic.clinicaltrials.gov/ct2/show/NCT04511221 accessed 26 September 2023
  26. A study investigating the safety, recovery, and pharmacodynamics of multiple oral administrations of SNIPR001 in healthy subjects - Full Text View - ClinicalTrials.gov. n.d https://classic.clinicaltrials.gov/ct2/show/NCT05277350 accessed 26 September 2023
  27. Bacteriophage Therapy TP-102 in Diabetic Foot Ulcers - Full Text View - ClinicalTrials.gov. n.d https://classic.clinicaltrials.gov/ct2/show/NCT04803708 accessed 26 September 2023
  28. A study to evaluate the safety, tolerability, and fecal pharmacokinetics of BX002-A in healthy adults - Full Text View - ClinicalTrials.gov. n.d https://classic.clinicaltrials.gov/ct2/show/NCT04737876 accessed 26 September 2023
  29. Ooi ML, Drilling AJ, Morales S, Fong S, Moraitis S et al. Safety and tolerability of bacteriophage therapy for chronic rhinosinusitis due to Staphylococcus aureus. JAMA Otolaryngol Head Neck Surg 2019; 145:723–729 [View Article] [PubMed]
     [Google Scholar]
  30. Cystic Fibrosis bacterioPHage Study at Yale (CYPHY) - Full Text View - ClinicalTrials.gov. n.d https://classic.clinicaltrials.gov/ct2/show/NCT04684641 accessed 23 September 2023
  31. Dedrick RM, Guerrero-Bustamante CA, Garlena RA, Russell DA, Ford K et al. Engineered bacteriophages for treatment of a patient with a disseminated drug-resistant Mycobacterium abscessus. Nat Med 2019; 25:730–733 [View Article] [PubMed]
     [Google Scholar]
  32. Cano EJ, Caflisch KM, Bollyky PL, Van Belleghem JD, Patel R et al. Phage therapy for lmb-threatening prosthetic knee Klebsiella pneumoniae infection: case report and in vitro characterization of anti-biofilm activity. Clin Infect Dis 2021; 73:e144–e151 [View Article] [PubMed]
     [Google Scholar]
  33. Cesta N, Pini M, Mulas T, Materazzi A, Ippolito E et al. Application of phage therapy in a case of a chronic hip-prosthetic joint infection due to Pseudomonas aeruginosa: an Italian real-life experience and in vitro analysis. Open Forum Infect Dis 2023; 10: [View Article]
     [Google Scholar]
  34. Ferry T, Kolenda C, Batailler C, Gustave C-A, Lustig S et al. Phage therapy as adjuvant to conservative surgery and antibiotics to salvage patients with relapsing S. aureus prosthetic knee infection. Front Med 2020; 7:570572 [View Article] [PubMed]
     [Google Scholar]
  35. Onsea J, Soentjens P, Djebara S, Merabishvili M, Depypere M et al. Bacteriophage application for difficult-to-treat musculoskeletal infections: development of a standardized multidisciplinary treatment protocol. Viruses 2019; 11:891 [View Article] [PubMed]
     [Google Scholar]
  36. Vandenheuvel D, Lavigne R, Brüssow H. Bacteriophage therapy: advances in formulation strategies and human clinical trials. Annu Rev Virol 2015; 2:599–618 [View Article] [PubMed]
     [Google Scholar]
  37. Jault P, Leclerc T, Jennes S, Pirnay JP, Que Y-A et al. Efficacy and tolerability of a cocktail of bacteriophages to treat burn wounds infected by Pseudomonas aeruginosa (PhagoBurn): a randomised, controlled, double-blind phase 1/2 trial. Lancet Infect Dis 2019; 19:35–45 [View Article] [PubMed]
     [Google Scholar]
  38. Gu J, Liu X, Li Y, Han W, Lei L et al. A method for generation phage cocktail with great therapeutic potential. PLoS One 2012; 7:e31698 [View Article] [PubMed]
     [Google Scholar]
  39. Ribeiro JM, Pereira GN, Durli Junior I, Teixeira GM, Bertozzi MM et al. Comparative analysis of effectiveness for phage cocktail development against multiple Salmonella serovars and its biofilm control activity. Sci Rep 2023; 13:13054 [View Article] [PubMed]
     [Google Scholar]
  40. Chan BK, Abedon ST. Phage therapy pharmacology phage cocktails. Adv Appl Microbiol 2012; 78:1–23 [View Article] [PubMed]
     [Google Scholar]
  41. Abedon ST, Danis-Wlodarczyk KM, Wozniak DJ. Phage cocktail development for bacteriophage therapy: toward improving spectrum of activity breadth and depth. Pharmaceuticals 2021; 14:1019 [View Article] [PubMed]
     [Google Scholar]
  42. Haines MEK, Hodges FE, Nale JY, Mahony J, van Sinderen D et al. Analysis of selection methods to develop novel phage therapy cocktails against antimicrobial resistant clinical isolates of bacteria. Front Microbiol 2021; 12:613529 [View Article] [PubMed]
     [Google Scholar]
  43. Pirnay JP, Ferry T, Resch G. Recent progress toward the implementation of phage therapy in Western medicine. FEMS Microbiol Rev 2022; 46: [View Article]
     [Google Scholar]
  44. Engeman E, Freyberger HR, Corey BW, Ward AM, He Y et al. Synergistic killing and re-sensitization of Pseudomonas aeruginosa to antibiotics by phage-antibiotic combination treatment. Pharmaceuticals 2021; 14:184 [View Article] [PubMed]
     [Google Scholar]
  45. Huon J-F, Montassier E, Leroy A-G, Grégoire M, Vibet M-A et al. Phages versus antibiotics to treat infected diabetic wounds in a mouse model: a microbiological and microbiotic evaluation. mSystems 2020; 5: [View Article]
     [Google Scholar]
  46. Liu CG, Green SI, Min L, Clark JR, Salazar KC et al. Phage-antibiotic synergy is driven by a unique combination of antibacterial mechanism of action and stoichiometry. Microbiology 111–19 [View Article]
     [Google Scholar]
  47. Doub JB, Ng VY, Johnson AJ, Slomka M, Fackler J et al. Salvage bacteriophage therapy for a chronic MRSA prosthetic joint infection. Antibiotics 2020; 9:241 [View Article]
     [Google Scholar]
  48. Ph 1/2 Study Evaluating Safety and Tolerability of Inhaled AP-PA02 in Subjects With Chronic Pseudomonas Aeruginosa Lung Infections and Cystic Fibrosis - Full Text View - ClinicalTrials.gov. n.d https://classic.clinicaltrials.gov/ct2/show/NCT04596319 accessed 26 September 2023
  49. Merrill JT, Neuwelt CM, Wallace DJ, Shanahan JC, Latinis KM et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 2010; 62:222–233 [View Article] [PubMed]
     [Google Scholar]
  50. Torres-Barceló C. Phage therapy faces evolutionary challenges. Viruses 2018; 10:323 [View Article] [PubMed]
     [Google Scholar]
  51. Ujmajuridze A, Chanishvili N, Goderdzishvili M, Leitner L, Mehnert U et al. Adapted bacteriophages for treating urinary tract infections. Front Microbiol 2018; 9: [View Article]
     [Google Scholar]
  52. MacNeal WJ. Specific therapeutic shock—the hugh young reaction. Arch Surg 1941; 43:579 [View Article]
     [Google Scholar]
  53. Desranleau JM. Progress in the treatment of typhoid fever with vi bacteriophages C. J Public Health 1949; 40:473–478
     [Google Scholar]
  54. Eiselt VA, Bereswill S, Heimesaat MM. Phage therapy in prosthetic joint infections caused by Staphylococcus aureus - a literature review. Eur J Microbiol Immunol 2024; 14:75–85 [View Article] [PubMed]
     [Google Scholar]
  55. Ferry T, Kolenda C, Batailler C, Gaillard R, Gustave C-A et al. Case report: arthroscopic “Debridement antibiotics and implant retention” with local injection of personalized phage therapy to salvage a relapsing Pseudomonas aeruginosa prosthetic knee infection. Front Med 2021; 8:569159 [View Article] [PubMed]
     [Google Scholar]
  56. Fish R, Kutter E, Bryan D, Wheat G, Kuhl S. Resolving digital Staphylococcal osteomyelitis using bacteriophage-a case report. Antibiotics 2018; 7:87 [View Article] [PubMed]
     [Google Scholar]
  57. Assessing the efficacy of anti-staphylococcal phages in the management of infected foot ulcers in diabetes - Full Text View - ClinicalTrials.gov. n.d https://classic.clinicaltrials.gov/ct2/show/NCT04289948 accessed 26 September 2023
  58. Cao B, Li Y, Yang T, Bao Q, Yang M et al. Bacteriophage-based biomaterials for tissue regeneration. Adv Drug Deliv Rev 2019; 145:73–95 [View Article] [PubMed]
     [Google Scholar]
  59. Azam AH, Tan X-E, Veeranarayanan S, Kiga K, Cui L. Bacteriophage technology and modern medicine. Antibiotics 2021; 10:999 [View Article] [PubMed]
     [Google Scholar]
  60. Aghebati-Maleki L, Bakhshinejad B, Baradaran B, Motallebnezhad M, Aghebati-Maleki A et al. Phage display as a promising approach for vaccine development. J Biomed Sci 2016; 23:66 [View Article]
     [Google Scholar]
  61. Garenne D, Noireaux V. Cell-free transcription–translation: engineering biology from the nanometer to the millimeter scale. Curr Opin Biotechnol 2019; 58:19–27 [View Article]
     [Google Scholar]
  62. Tridgett M, Ababi M, Osgerby A, Ramirez Garcia R, Jaramillo A. Engineering bacteria to produce pure phage-like particles for gene delivery. ACS Synth Biol 2021; 10:107–114 [View Article] [PubMed]
     [Google Scholar]
  63. Du J, Meile S, Baggenstos J, Jäggi T, Piffaretti P et al. Enhancing bacteriophage therapeutics through in situ production and release of heterologous antimicrobial effectors. Nat Commun 2023; 14:4337 [View Article]
     [Google Scholar]
  64. Macdonald KE, Stacey HJ, Harkin G, Hall LML, Young MJ et al. Patient perceptions of phage therapy for diabetic foot infection. PLoS One 2020; 15:e0243947 [View Article] [PubMed]
     [Google Scholar]
/content/journal/jmm/10.1099/jmm.0.001895
Loading
Current status of clinical trials for phage therapy
J. Med. Microbiol. 73, 001895 (2024); https://doi.org/10.1099/jmm.0.001895
/content/journal/jmm/10.1099/jmm.0.001895
/content/journal/jmm/10.1099/jmm.0.001895
Loading

Data & Media loading...

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error